MiMedx Group, Inc. (MDXG) stock
Close on Nov 18, 2026Market cap $464.04MP/E –Yield –
Earnings
MiMedx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of MiMedx's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 28, 2026after the close | $62.00M | – | -$0.06 | -$0.01 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026after the close | $64.00M | -35.4% | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 29, 2026after the close | $59.00M | -33.0% | -$0.07 | -$0.05 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026after the close | $118.00M | +26.9% | $0.10 | $0.14 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025after the close | – | – | – | $0.15 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 30, 2025after the close | $99.00M | +13.8% | $0.06 | $0.10 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 30, 2025after the close | $88.00M | +3.5% | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025after the close | $93.00M | +6.9% | $0.05 | $0.07 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 30, 2024after the close | $84.00M | +2.8% | $0.05 | $0.07 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024after the close | $87.00M | +7.0% | $0.12 | $0.08 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 30, 2024after the close | $85.00M | +18.5% | $0.06 | $0.07 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024after the close | $87.00M | +16.9% | $0.32 | $0.04 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 30, 2023after the close | $81.70M | +20.7% | $0.06 | $0.05 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 1, 2023after the close | $81.30M | +21.5% | $0.00 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 2, 2023after the close | $71.70M | +21.7% | -$0.06 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023after the close | $74.40M | +10.4% | -$0.02 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022after the close | $67.70M | +7.3% | -$0.09 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022after the close | $66.90M | – | -$0.11 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022after the close | $58.90M | – | -$0.11 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022after the close | $67.40M | – | $0.01 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021after the close | $63.10M | – | -$0.04 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 3, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 9, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
MiMedx's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| net salesGAAP | FY2026 | $250.00M – $260.00M | – | New | Oct 28, 2026 |
| net sales | FY2026 | $260.00M – $290.00M | $260.00M – $290.00M | Reaffirmed | Jul 29, 2026 |
Guidance vs results
The last range MiMedx gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q4 FY2022 | Revenue | $73.00M – $76.00M | $74.40M | Within range |
Guidance history
Every forecast MiMedx put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 28, 2026 | net sales | FY2026 | $250.00M – $260.00M | New |
| Jul 29, 2026 | net sales | FY2026 | $260.00M – $290.00M | Reaffirmed |
| Apr 29, 2026 | net sales | FY2026 | $260.00M – $290.00M | Lowered |
| Feb 25, 2026 | net sales | FY2026 | $340.00M – $360.00M | New |
| Jul 30, 2025 | Adjusted EBITDA margin | FY2025 | 20% | Reaffirmed |
| Apr 30, 2025 | Adjusted EBITDA margin | FY2025 | 20% | New |
| Feb 26, 2025 | Adjusted EBITDA margin | FY2025 | 20% | New |
| Oct 30, 2024 | Adjusted EBITDA margin | FY2024 | 20% | New |
| Feb 28, 2024 | Adjusted EBITDA as a percent of net sales | FY2024 | 20% | New |
| Oct 30, 2023 | Adjusted EBITDA margin | FY2023 | 20% | Reaffirmed |
| Oct 30, 2023 | cash on the balance sheet | Q4 FY2023 | $80.00M | New |
| Aug 1, 2023 | Adjusted EBITDA margin | FY2023 | 20% | New |
| Nov 2, 2022 | net sales | Q4 FY2022 | $73.00M – $76.00M | New |
| Nov 2, 2022 | net sales | FY2022 | $266.00M – $269.00M | New |
| Aug 2, 2022 | net sales of its continuing portfolio of Advanced Wound Care products | FY2022 | +11% – +14% | Reaffirmed |
| May 3, 2022 | net sales of its continuing portfolio of Advanced Wound Care products | FY2022 | +11% – +14% | Reaffirmed |
| Feb 28, 2022 | net sales of its continuing portfolio of products | FY2022 | +11% – +14% | New |
| Jan 10, 2022 | R&D spend | FY2022 | $22.00M | New |
| Jan 10, 2022 | Net Sales | FY2021 | $254.00M – $259.00M | New |
| Jan 10, 2022 | Adjusted Net Sales | FY2021 | $253.00M – $258.00M | Raised |
| Jan 10, 2022 | Annual revenue growth | FY2022 | +11% – +14% | New |
| Nov 2, 2021 | adjusted net sales | FY2021 | $245.00M – $255.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases MiMedx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Update
- Results
- Results
- Results
See a number that looks wrong?